MedTrace Logo

Podocan and Wnt Pathway in the Development of Aortopathy in Bicuspid Valve Disease

NCT02806310 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 29

Last updated 2022-03-02

No results posted yet for this study

Summary

Bicuspid Aortic Valve (BAV) disease is a common cardiac anomaly that is associated with valvular abnormalities, both stenosis and regurgitation, and aortopathy. It is also shown to play role in abnormal aortic distensibility and stiffness with impairment of aortic elasticity and Left ventricular dysfunction. Mechanism of aortopathy is complex and is not understood completely. In a recent study podocan is found in extracellular matrix (ECM) of human aorta and is found to be accumulated in human abdominal aortic aneurysms. There is no current effective therapy that can alter the progression of aortic dilatation in bicuspid valve disease. Aortic surgery and aortoplasty is the only treatment in severely dilated aorta and aortic dissection. In this study the aim is to investigate the association between podocan and Wnt pathway in development and pathogenesis of aortopathy. This could provide more effective and physiological understanding of disease process and potential target in prevention and treatment for aortopathy.

Conditions

  • Aortic Valve Disease

Interventions

OTHER

Blood draw

blood sampling for biomarker levels

Sponsors & Collaborators

  • Bassett Healthcare

    lead OTHER

Principal Investigators

  • daniel Katz, MD · Bassett Healthcare

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02806310 on ClinicalTrials.gov